Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative / myelodysplastic disorders : an analysis of 636 cases

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.

[1]  M. García-Delgado,et al.  CBL mutations in myeloproliferative neoplasms are also found in the gene’s proline-rich domain and in patients with the V617FJAK2 , 2012, Haematologica.

[2]  A. Kohlmann,et al.  ASXL1 exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with An Extremely Poor Outcome , 2011 .

[3]  Michael A McDevitt,et al.  CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. , 2011, Blood.

[4]  A. Kohlmann,et al.  A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases , 2011, Leukemia.

[5]  A. Kohlmann,et al.  Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance , 2011, Leukemia.

[6]  Martin Dugas,et al.  Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Kusec,et al.  Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. , 2010, Blood.

[8]  A. Kohlmann,et al.  Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis , 2010, Haematologica.

[9]  M. Loh,et al.  Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. , 2009, Blood.

[10]  S. Ogawa,et al.  Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms , 2009, Nature.

[11]  W. Hiddemann,et al.  CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes , 2009, Clinical Cancer Research.

[12]  T. Haferlach,et al.  Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera , 2009, Haematologica.

[13]  M. McDevitt,et al.  250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. , 2008, Cancer research.

[14]  A. Hall,et al.  Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. , 2008, Blood.

[15]  T. Haferlach,et al.  Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis , 2008, Leukemia.

[16]  T. Haferlach,et al.  Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. , 2007, Blood.

[17]  T. Haferlach,et al.  Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E , 2006, Leukemia.

[18]  T. Seriu,et al.  Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology , 2000, Leukemia.

[19]  R. Arceci.  Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies , 2010 .

[20]  Professor Dr. med. Helmut Löffler,et al.  Atlas of Clinical Hematology , 2000, Springer Berlin Heidelberg.

[21]  J. Melo,et al.  An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. , 1994, Leukemia.